Oncology Central

IMpower130: Tecentriq® scores big in pivotal NSCLC trial

0
Roche (Basel, Switzerland) has announced results from its Phase III IMpower130 trial. The findings demonstrate that Tecentriq® (atezolizumab) plus chemotherapy (carboplatin and Abraxane®) helped individuals with metastatic non-squamous non-small cell lung cancer (NSCLC), who lived significantly longer compared with those who received chemotherapy alonelive significantly longer compared with chemotherapy alone.
To view restricted content, please:
Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.